SWOG Biospecimen Bank to Support NCI NCTN

SWOG 生物样本库将支持 NCI NCTN

基本信息

批准号：
10610408
负责人：
NILSA DEL CARMEN RAMIREZ MILAN
金额：
$ 330.64万
依托单位：
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-04-23 至 2026-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10610408
关键词：
Address Adult Biological Specimen Banks Breast Cancer Patient Clinical Clinical Data Clinical Medicine Clinical Research Clinical Treatment Clinical Trials Clinical Trials Information for Patients Collaborations Collection Colon Component of the National Cancer Institute Coupled Data Data Coordinating Center Data Reporting Diagnostic Disease Ensure Epidemiology Goals Guidelines Health protection Human Immunologic Monitoring Laboratories Link Lung Lymphoma Malignant Neoplasms Marketing Molecular Biology Molecular Profiling Multiple Myeloma National Cancer Institute National Clinical Trials Network Operative Surgical Procedures Pathologic Patients Pediatric Hospitals Policies Procedures Process Prostate Protocols documentation Qualifying Quality Control Reporting Research Research Institute Research Personnel Residual state Resources Sampling Services Site Southwest Oncology Group System Technology Therapeutic Translational Research Treatment Protocols Work anticancer research biobank cancer clinical trial cancer prevention cancer type clinical trial protocol data management data sharing design experience follow-up improved improved outcome innovative technologies laboratory equipment leukemia melanoma operation participant enrollment programs targeted treatment therapy outcome translational medicine tumor

Address Adult Biological Specimen Banks Breast Cancer Patient Clinical Clinical Data Clinical Medicine Clinical Research Clinical Treatment Clinical Trials Clinical Trials Information for Patients Collaborations Collection Colon Component of the National Cancer Institute Coupled Data Data Coordinating Center Data Reporting Diagnostic Disease Ensure Epidemiology Goals Guidelines Health protection Human Immunologic Monitoring Laboratories Link Lung Lymphoma Malignant Neoplasms Marketing Molecular Biology Molecular Profiling Multiple Myeloma National Cancer Institute National Clinical Trials Network Operative Surgical Procedures Pathologic Patients Pediatric Hospitals Policies Procedures Process Prostate Protocols documentation Qualifying Quality Control Reporting Research Research Institute Research Personnel Residual state Resources Sampling Services Site Southwest Oncology Group System Technology Therapeutic Translational Research Treatment Protocols Work anticancer research biobank cancer clinical trial cancer prevention cancer type clinical trial protocol data management data sharing design experience follow-up improved improved outcome innovative technologies laboratory equipment leukemia melanoma operation participant enrollment programs targeted treatment therapy outcome translational medicine tumor

展开

项目摘要

Project Summary SWOG is an adult clinical trials cancer group within the National Clinical Trials Network (NCTN) of the National Cancer Institute (NCI). SWOG clinical trials include a range of cancer types (e.g., breast, lung, colon, prostate, leukemia, melanoma, lymphoma, and multiple myeloma). The SWOG Biospecimen Bank (Biobank), located in the Biopathology Center (part of the Abigail Wexner Research Institute of Nationwide Children's Hospital), was designed to procure, process, bank, and distribute biospecimens collected as a major component of NCI- sponsored clinical trials. These biospecimens are linked to demographic information, surgical and pathological reports, and treatment and follow-up data of study participants enrolled on SWOG protocols. Upon review and approval, biospecimens are prioritized for distribution to the specific SWOG investigators defined in the clinical trial protocols. After the needs of the planned research have been addressed, residual (legacy) banked biospecimens can be distributed to other investigators within and outside SWOG via the NCTN Navigator. The SWOG Group and Biobank Concierges can also facilitate access to SWOG legacy biospecimens that are not currently uploaded in Navigator. This process has been designed to mirror the process for legacy biospecimens on the Navigator system and includes a feasibility assessment by the SWOG Biobank and the SWOG Statistical and Data Management Center prior to proposal submission. The Biobank is a functioning and viable part of SWOG's clinical and translational medicine program, and focuses on the integration of diagnostic, therapeutic, laboratory, and clinical data to answer questions in clinical and translational research. The SWOG Biobank works under the hypothesis that banking of high quality, clinically-annotated and cancer- related human biospecimens, linked to molecular signatures/markers, will significantly facilitate and further advance clinical cancer research. To support this effort, the SWOG Biobank manages these biospecimens under strict guidelines and standard operating procedures based on current Best Practices for biorepositories and the latest laboratory technologies. The Biobank's experience, coupled with a firm commitment to quality and integrity operations, makes it uniquely able to provide an accurate and effective resource of tumor and normal samples with associated clinical, epidemiologic, and protected health information. The SWOG Biobank aims to harmonize and expand general banking practices and innovative technologies, which will continue to facilitate molecular biology research and increase investigator participation in clinical research trials via the NCI-sponsored Group Banking Committee (GBC). The SWOG Biobank also plans to support the processing, banking, and distribution of biospecimens to the Cancer Immune Monitoring and Analysis Centers (CIMACs).

项目摘要 SWOG是国家临床试验网络（NCTN）中的成人临床试验癌组癌症研究所（NCI）。 SWOG临床试验包括一系列癌症类型（例如乳腺癌，肺，结肠，前列腺，前列腺，白血病，黑色素瘤，淋巴瘤和多发性骨髓瘤）。 Swog Biospecimen Bank（Biobank），位于生物病理学中心（阿比盖尔·韦克斯纳（Abigail Wexner）全国儿童医院研究所的一部分）是旨在采购，处理，银行和分发作为NCI-的主要组成部分收集的生物测量。赞助临床试验。这些生物测量与人口统计信息，外科和病理有关研究参与者的报告，治疗和随访数据参加了SWOG方案。在审查和批准，将生物测量优先为分配给临床定义的特定SWOG研究者试验方案。在解决了计划研究的需求之后，剩余（遗产）库存可以通过NCTN导航器将生物测量分配给摇摆内外的其他研究人员。这 Swog Group和Biobank Concierges还可以促进不访问不是当前已上传在导航器中。此过程旨在反映遗产的过程导航器系统上的生物测量，包括Swog Biobank和The的可行性评估提交提交之前，请溶解统计和数据管理中心。生物库是一个功能以及Swog的临床和转化医学计划的可行一部分，并重点介绍诊断，治疗，实验室和临床数据，以回答临床和转化研究中的问题。 Swog Bioband的作品是基于一个假设，即高质量，临床注释和癌症的库存。与分子特征/标记相关的相关人类生物测量将显着促进并进一步预先临床癌症研究。为了支持这一努力，Swog Biobank管理着这些生物测量根据严格的指南和标准操作程序，基于当前的生物局限器的最佳实践以及最新的实验室技术。生物库的经验，加上对质量的坚定承诺和完整性操作，使其具有独特的能力，以提供肿瘤的准确和有效资源具有相关临床，流行病学和受保护的健康信息的正常样品。 swog生物库旨在协调和扩展一般银行业务和创新技术，这将继续促进分子生物学研究并增加研究者参与临床研究试验 NCI赞助的集团银行委员会（GBC）。 Swog Biobank还计划支持处理，银行和生物测量分配给癌症免疫监测和分析中心（CIMACS）。